Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cCTL and Immunotherapy in Advanced Gynecologic Malignancies
NCT07434284Phase 1Recruiting
- Sponsor
- Obstetrics and Gynecology Hospital of Fudan University
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in gynecologic malignancy, ovarian cancer, Cervical Cancer (CC) and 1 more, sponsored by Obstetrics and Gynecology Hospital of Fudan University. Primary endpoint: Objective Response Rate at 8 weeks. Started Feb 2026; status: recruiting.
02
Conditions
gynecologic malignancyovarian cancerCervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07434284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07434284.